GlassScriptPhysician profile
Amy C Campion
NPI 1548352073
$7,703.20
in general payments reported to CMS, 2019-2025
44 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $599 · 2021: $988 · 2022: $1,266 · 2023: $1,538 · 2024: $1,078 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,926 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,926.47 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $784.43 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $782.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $635.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $510.29 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Janssen Pharmaceuticals, INC | $403.77 | 2019-2025 | Spravato, Xarelto |
| Lundbeck LLC | $396.73 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $391.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $383.42 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Astellas Pharma US INC | $365.90 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $341.59 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $335.26 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Amgen INC. | $308.16 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $230.48 | 2019-2024 | |
| Abbvie INC. | $203.62 | 2022-2025 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.57 | 2019-2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $152.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $146.72 | 2019-2025 | Eliquis |
| Sunovion Pharmaceuticals INC. | $122.43 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $118.46 | 2020-2022 | |
| Abbott Laboratories | $110.45 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $91.98 | 2022 | |
| Neurocrine Biosciences, INC. | $68.41 | 2024 | Ingrezza |
| Indivior INC. | $55.12 | 2025 | Sublocade |
| Biohaven Pharmaceuticals, INC. | $49.70 | 2021 | |
| Avanir Pharmaceuticals, INC. | $47.99 | 2021-2022 | |
| Daiichi Sankyo INC. | $45.88 | 2022 | |
| Amarin Pharma, INC. | $44.75 | 2021 | |
| Bioventus LLC | $34.50 | 2019 | |
| Exeltis, USA INC. | $34.17 | 2022-2024 | Slynd |
| Seqirus USA INC | $31.85 | 2019-2022 | |
| Sanofi Pasteur INC. | $29.93 | 2024-2025 | |
| Ucb, INC. | $29.61 | 2023 | Nayzilam |
| Allergan, INC. | $27.28 | 2020 | |
| Soleno Therapeutics, INC. | $23.84 | 2025 | Vykat Xr |
| Scilex Pharmaceuticals INC. | $22.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $21.77 | 2025 | Zoryve |
| Jazz Pharmaceuticals INC. | $20.98 | 2022 | |
| Esperion Therapeutics, INC. | $20.68 | 2020 | |
| Axsome Therapeutics, INC. | $20.52 | 2025 | Auvelity |
| Aimmune Therapeutics, INC. | $20.52 | 2025 | Zenpep |
| Ardelyx, INC. | $19.56 | 2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $17.06 | 2021 | |
| Alkermes, INC. | $13.66 | 2025 | Vivitrol |
| Corium, LLC | $12.96 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Campion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.